Diabetologie und Stoffwechsel 2017; 12(S 01): S1-S84
DOI: 10.1055/s-0037-1601732
Poster: *Poster + Kurzpräsentation
Typ-2-Diabetes II – Pathophysiologie
Georg Thieme Verlag KG Stuttgart · New York

Nutritional intervention by a novel slow-release niacin formulation beneficially alters the gut microbiome and promotes systemic metabolic effects in humans

D Fangmann
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
,
EM Theismann
2   Department of Food Technology, University of Kiel, Kiel, Germany
,
K Türk
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
,
DM Schulte
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
,
I Relling
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
,
K Hartmann
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
,
J Keppler
2   Department of Food Technology, University of Kiel, Kiel, Germany
,
J Knipp
2   Department of Food Technology, University of Kiel, Kiel, Germany
,
A Rehmann
3   Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany
,
S Freitag-Wolf
4   Institute of Medical Informatics and Statistics, University of Kiel, Kiel, Germany
,
G Wätzig
5   CONARIS Research Institute AG, Kiel, Germany
,
D Seegert
5   CONARIS Research Institute AG, Kiel, Germany
,
P Rosenstiel
3   Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany
,
K Schwarz
2   Department of Food Technology, University of Kiel, Kiel, Germany
,
S Schreiber
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
3   Institute of Clinical Molecular Biology, University of Kiel, Kiel, Germany
,
M Laudes
1   Department of Internal Medicine 1, University Hospital Schleswig-Holstein, Kiel, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
05 May 2017 (online)

Also available at
 

Obesity and type 2 diabetes have been linked to abnormalities in the gut microbiota. In animal models, administration of Niacin (Vitamin B3), which is a major metabolite of cellular tryptophan metabolism, beneficially affects the microbiome-host axis. By measuring Niacin levels in n = 511 humans we found reduced concentrations in obese and type 2 diabetic subjects, suggesting Niacin administration to be beneficial also in humans. However, orally administration of Niacin in humans rapidly results in systemic resorption in the upper gastro-intestinal (GI) tract leading to a facial flush. Therefore, in the present study we developed a novel microencapsulation procedure using food grade ingredients in order to prevent resorption of Niacin in the upper GI tract and enabling a sufficient release of the nutrient in the ileo-colonic region. In a first human intervention trial we were able to show that the microencapsulation procedure efficiently prevents systemic resorption and that no severe side effects and no flush occur. Fecal 16sDNA microbiome sequencing revealed significant changes in the Bacteroidetes in response to orally administered microencapsulated Niacin. Of importance, microencapsulated Niacin but not naïve Niacin resulted in beneficial systemic metabolic effects, suggesting an indirect mechanism via the microbiome rather than a direct effect of the nutrient itself. In summary, our data suggest that a targeted microbiome intervention using advanced food technology is able to induce beneficial systemic metabolic effects in humans. Thus, food enriched with microencapsulated Niacin might be a novel prevention/treatment option for obesity and type 2 diabetes in the future.